Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)

NCT05828901 · clinicaltrials.gov ↗

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped not sufficient funding

Conditions

Multiple Sclerosis

Interventions

OTHER: S1PR analysis on immune cells

Sponsor

Insel Gruppe AG, University Hospital Bern